MYCOPHENOLATE MOFETIL AND THE INCIDENCE OF SKIN CANCER IN KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Yusuf, Sarah [1 ]
Bheemreddy, Himaja [1 ]
Ahmed, Imtiaz [2 ]
Krishnan, Nithya [3 ]
机构：
[1] Coventry Univ, Fac Hlth & Life Sci, Coventry, W Midlands, England
[2] Univ Hosp Coventry & Warwickshire, Dermatol, Coventry, W Midlands, England
[3] Univ Hosp Coventry & Warwickshire, Renal Transplantat & Nephrol, Coventry, W Midlands, England
来源：
TRANSPLANTATION | 2020年 / 104卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P-18.02
引用
收藏
页码：S603 / S603
页数：1
相关论文
共 50 条
  • [31] Skin cancer in kidney transplant recipients
    Ponticelli, Claudio
    Cucchiari, David
    Bencini, PierLuca
    JOURNAL OF NEPHROLOGY, 2014, 27 (04) : 385 - 394
  • [32] Skin cancer in kidney transplant recipients
    Claudio Ponticelli
    David Cucchiari
    PierLuca Bencini
    Journal of Nephrology, 2014, 27 : 385 - 394
  • [33] Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients
    Hanvesakul, Rajesh
    Kubal, Chandrashekhar
    Jham, Seema
    Sarkar, Esha
    Eardley, Kevin
    Adu, Dwomoa
    Cockwell, Paul
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (12) : 4049 - 4053
  • [34] Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients
    Sunder-Plassmann, Gere
    Reinke, Petra
    Rath, Thomas
    Wiecek, Andrzej
    Nowicki, Michal
    Moore, Richard
    Lutz, Jens
    Gaggl, Martina
    Ferkl, Marek
    TRANSPLANT INTERNATIONAL, 2012, 25 (06) : 680 - 686
  • [35] Cost-effectiveness of mycophenolate mofetil monitoring and dose adjustment in kidney transplant recipients
    Laroche, M. L.
    Marquet, P.
    Vergnenegre, A.
    Jacqz-Aigrain, E.
    Saivin, S.
    Debruyne, D.
    Turcant, A.
    Grima, M.
    Venisse, N.
    Hary, L.
    Compagnon, P.
    Hoizey, G.
    Le Meur, Y.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 38 - 39
  • [36] Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
    Ahsan, N
    Hricik, D
    Matas, A
    Rose, S
    Tomlanovich, S
    Wilkinson, A
    Ewell, M
    McIntosh, M
    Stablein, D
    Hodge, E
    Hayes, D
    Gores, P
    Cohen, D
    Gonwa, T
    Brinler, K
    Harland, R
    Neylan, J
    Pescovitz, M
    Wynn, J
    Ahsan, N
    Yang, HC
    Bennett, W
    Copley, J
    Wilkinson, A
    Dunn, J
    Tomlanovich, S
    Chan, L
    Bertolatus, JA
    Weir, M
    Mendez, R
    Pirsch, J
    Helderman, JH
    TRANSPLANTATION, 1999, 68 (12) : 1865 - 1874
  • [37] Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine
    Lobritto, Steven J.
    Rosenthal, Philip
    Bouw, Rene
    Leung, Mimi
    Snell, Paul
    Mamelok, Richard D.
    LIVER TRANSPLANTATION, 2007, 13 (11) : 1570 - 1575
  • [38] Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone
    ter Meulen, CG
    Gregoor, PJHS
    Weimar, W
    Hilbrands, LB
    TRANSPLANT INTERNATIONAL, 2001, 14 (02) : 99 - 102
  • [39] Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients
    Navascués, RA
    Gómez, E
    Rodriguez, M
    Laures, AS
    Baltar, J
    Grande, JA
    NEPHRON, 2002, 91 (01) : 173 - 174
  • [40] Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil.
    Takamoto, D.
    Sasaki, H.
    Harada, S.
    Takada, Y.
    Harada, H.
    Tsujimoto, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 1088 - 1088
12345